Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT

King Faisal Specialist Hospital & Research Center10 enrolled

Overview

Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma or Hodgkin's Disease

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lymphoma, Non-Hodgkin Hodgkin Disease

Interventions

FDG PETPROCEDURE

FDG PET

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with NHL and HD undergoing HDC and ASCT

Outcomes

Primary Outcomes

Prognosis

Time frame: overall

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.